ALLO-647 is named as an intervention in 2 current clinical trials in our USA register. None are recruiting at the moment. The most common phase is Phase 1. The lead sponsor is Allogene Therapeutics. The most-studied condition is Advanced/Metastatic Clear Cell Renal Cell Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
NCT04416984 · ClinicalTrials.gov ↗ · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
|
Phase 1/2 | Active, closed | Allogene Therapeutics | USA |
|
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04696731 · Advanced/Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 1 | Active, closed | Allogene Therapeutics | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Allogene Therapeutics | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA register name ALLO-647 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Allogene Therapeutics. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ALLO-647 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ALLO-647 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ALLO-647 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.